Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis
AIM: To evaluate and compare the anatomical and functional outcomes and negative effects of the three anti-vascular endothelial growth factor (VEGF) drugs in the treatment of macular edema (ME) due to retinal vein occlusion (RVO) based on the evidence pooled from current clinical trials and observat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2023-07-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://ies.ijo.cn/en_publish/2023/7/20230721.pdf |
| _version_ | 1797794073211305984 |
|---|---|
| author | Qiu Xing Ya-Nan Dai Xiao-Bo Huang Li Peng |
| author_facet | Qiu Xing Ya-Nan Dai Xiao-Bo Huang Li Peng |
| author_sort | Qiu Xing |
| collection | DOAJ |
| description | AIM: To evaluate and compare the anatomical and functional outcomes and negative effects of the three anti-vascular endothelial growth factor (VEGF) drugs in the treatment of macular edema (ME) due to retinal vein occlusion (RVO) based on the evidence pooled from current clinical trials and observational studies. METHODS: A systematic literature search was conducted on nine online databases from inception until April 30, 2022. The main endpoints were best corrected visual acuity (BCVA), central macular thickness (CMT), and adverse events (AEs). Cumulative Meta-analysis was conducted to synthesize the outcomes of the drugs. The retrieved data were analyzed using Stata software (version 12.0). RESULTS: A total of 20 studies comprising 1674 eyes met the inclusion criteria to the Meta-analysis. It was observed that conbercept and aflibercept had better visual acuity effects compared with ranibizumab at 1mo [weight mean difference (WMD)=-0.03, P=0.001; WMD=-0.05, P=0.019], but the effects were not different from that of ranibizumab at 6mo. Moreover, there was not statistically significant difference in the proportion of patients gaining ≥15 letters at 12-24mo between aflibercept and ranibizumab [odds ratio (OR)=1.16, P=0.427]. Conbercept had higher mean CMT change effects at 1mo (WMD= -14.43, P=0.014) and 6mo (WMD=-35.63, P≤0.001) compared with ranibizumab. Meanwhile, the mean CMT change effects at 1mo (WMD=-10.14, P=0.170), 6mo (WMD=-26.98, P=0.140) and 12-24mo (WMD=-12.34, P=0.071) were comparable among the groups. Similarly, AEs were not significantly different among the treatments (OR=0.75, P=0.305; OR=1.04, P=0.89). The stability of effect size of mean BCVA and CMT improved with the increase in sample size. Aflibercept and conbercept required fewer injections compared with ranibizumab. CONCLUSION: This is the first study to evaluate the efficacy and AEs of intravitreal administration of conbercept, ranibizumab, and aflibercept in the treatment of RVO-ME. Intravitreal aflibercept or conbercept results in better mean change in vision and CMT reduction compared with ranibizumab. Conbercept can be considered to be a promising and innovative drug with good anti-VEGF effects. |
| first_indexed | 2024-03-13T02:57:33Z |
| format | Article |
| id | doaj.art-606dfae2c90b41859264375cfd689800 |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-03-13T02:57:33Z |
| publishDate | 2023-07-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-606dfae2c90b41859264375cfd6898002023-06-28T02:15:05ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982023-07-011671145115410.18240/ijo.2023.07.2120230721Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysisQiu Xing0Ya-Nan Dai1Xiao-Bo Huang2Li Peng3Li Peng. Department of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, 43 People Road, Haikou 570000, Hainan Province, China. mj.pengli@163.comDepartment of Ophthalmology, the Changsha Central Affiliated Hospital, Hengyang Medical School, University of South China, Changsha 410004, Hunan Province, ChinaDepartment of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570000, Hainan Province, ChinaDepartment of Ophthalmology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570000, Hainan Province, China; Department of Ophthalmology, the Second Xiangya Hospital of Central South University, Changsha 410000, Hunan Province, ChinaAIM: To evaluate and compare the anatomical and functional outcomes and negative effects of the three anti-vascular endothelial growth factor (VEGF) drugs in the treatment of macular edema (ME) due to retinal vein occlusion (RVO) based on the evidence pooled from current clinical trials and observational studies. METHODS: A systematic literature search was conducted on nine online databases from inception until April 30, 2022. The main endpoints were best corrected visual acuity (BCVA), central macular thickness (CMT), and adverse events (AEs). Cumulative Meta-analysis was conducted to synthesize the outcomes of the drugs. The retrieved data were analyzed using Stata software (version 12.0). RESULTS: A total of 20 studies comprising 1674 eyes met the inclusion criteria to the Meta-analysis. It was observed that conbercept and aflibercept had better visual acuity effects compared with ranibizumab at 1mo [weight mean difference (WMD)=-0.03, P=0.001; WMD=-0.05, P=0.019], but the effects were not different from that of ranibizumab at 6mo. Moreover, there was not statistically significant difference in the proportion of patients gaining ≥15 letters at 12-24mo between aflibercept and ranibizumab [odds ratio (OR)=1.16, P=0.427]. Conbercept had higher mean CMT change effects at 1mo (WMD= -14.43, P=0.014) and 6mo (WMD=-35.63, P≤0.001) compared with ranibizumab. Meanwhile, the mean CMT change effects at 1mo (WMD=-10.14, P=0.170), 6mo (WMD=-26.98, P=0.140) and 12-24mo (WMD=-12.34, P=0.071) were comparable among the groups. Similarly, AEs were not significantly different among the treatments (OR=0.75, P=0.305; OR=1.04, P=0.89). The stability of effect size of mean BCVA and CMT improved with the increase in sample size. Aflibercept and conbercept required fewer injections compared with ranibizumab. CONCLUSION: This is the first study to evaluate the efficacy and AEs of intravitreal administration of conbercept, ranibizumab, and aflibercept in the treatment of RVO-ME. Intravitreal aflibercept or conbercept results in better mean change in vision and CMT reduction compared with ranibizumab. Conbercept can be considered to be a promising and innovative drug with good anti-VEGF effects.http://ies.ijo.cn/en_publish/2023/7/20230721.pdfanti-vascular endothelial growth factorconberceptafliberceptranibizumabmacular edemaretinal vein occlusion |
| spellingShingle | Qiu Xing Ya-Nan Dai Xiao-Bo Huang Li Peng Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis International Journal of Ophthalmology anti-vascular endothelial growth factor conbercept aflibercept ranibizumab macular edema retinal vein occlusion |
| title | Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis |
| title_full | Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis |
| title_fullStr | Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis |
| title_full_unstemmed | Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis |
| title_short | Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis |
| title_sort | comparison of efficacy of conbercept aflibercept and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion a meta analysis |
| topic | anti-vascular endothelial growth factor conbercept aflibercept ranibizumab macular edema retinal vein occlusion |
| url | http://ies.ijo.cn/en_publish/2023/7/20230721.pdf |
| work_keys_str_mv | AT qiuxing comparisonofefficacyofconberceptafliberceptandranibizumabophthalmicinjectioninthetreatmentofmacularedemacausedbyretinalveinocclusionametaanalysis AT yanandai comparisonofefficacyofconberceptafliberceptandranibizumabophthalmicinjectioninthetreatmentofmacularedemacausedbyretinalveinocclusionametaanalysis AT xiaobohuang comparisonofefficacyofconberceptafliberceptandranibizumabophthalmicinjectioninthetreatmentofmacularedemacausedbyretinalveinocclusionametaanalysis AT lipeng comparisonofefficacyofconberceptafliberceptandranibizumabophthalmicinjectioninthetreatmentofmacularedemacausedbyretinalveinocclusionametaanalysis |